FrancophonIA/ELRC3.0 huggingface dataset:
English: After treatment of the nematode infections, further flea and tick treatment should be continued with a mono-active product.
Estonian: Pärast nematoodiinfektsiooni ravi tuleb kirpude ja puukide tõrjet jätkata monoaktiivse ravimiga.
English: A single administration also prevents lungworm disease (by reducing the immature adults (L5) of A. vasorum) and heartworm disease (D. immitis) for one month.
Estonian: Ühekordne manustamine ennetab kuu aega ka kopsuusstõbe (vähendades A. vasorum'i ebaküpsete täiskasvanute (L5) hulka ja südameusstõbe (D. immitis).
English: When the product replaces another lungworm or heartworm preventive product, the first dose of the product should be given within a month of the last dose of the former veterinary medicinal product.
Estonian: Ühe kopsu- või südameusside vastase profülaktilise preparaadi asendamisel teisega tuleb esimene annus manustada ühe kuu jooksul pärast eelmise ravimi viimase annuse manustamist.
English: Pyrantel is eliminated through faeces and the small absorbed portion is eliminated mainly via urine.
Estonian: Püranteel eritub roojaga ja väike imendunud osa eritub peamiselt uriiniga.
English: The prandial state of the dogs does not affect the extent of absorption of sarolaner and moxidectin.
Estonian: Koera söötmine ei mõjuta sarolaneeri ega moksidektiini imendumist.
English: Sarolaner does not interact with known insecticidal binding sites of nicotinic or other GABAergic insecticides such as neonicotinoids, fiproles, milbemycins, avermectins, and cyclodienes.
Estonian: Sarolaneeril puudub koostoime nikotiin- või muude GABA-ergiliste insektitsiidide, näiteks neonikotinoidide, fiproolide, milbemütsiinide, avermektiinide ja tsüklodieenide teadaolevate insektitsiidsete sidumiskohtadega.
English: pyrantel (as embonate) (mg)
Estonian: püranteel (embonaadina) (mg)
English: Following receptor binding, the channel opens to allow the influx of cations resulting in a depolarization and excitatory effects on nematode muscle, ultimately leading to spastic paralysis of the worm and death.
Estonian: Retseptoriga seondumise järel avaneb kanal, mis võimaldab katioonide sissevoolu, tekitades depolarisatsiooni ja nematoodi lihaste erutusnähte, mille tulemuseks on parasiidi spastiline paralüüs ja surm.
English: Colorants: Sunset Yellow FCF (E110), Allura Red (E129), Indigo Carmine (E132).
Estonian: Värvained: päikeseloojangukollane FCF (E 110), võlupunane (E 129), indigokarmiin (E 132).
English: Sarolaner is active against adult fleas (Ctenocephalides felis and Ctenocephalides canis) as well as several tick species such as Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus.
Estonian: Sarolaneer toimib täiskasvanud kirpude (Ctenocephalides felis'e ja Ctenocephalides canis'e) ning mitmete puugiliikide, näiteks Dermacentor reticulatus'e, Ixodes hexagonus'e, Ixodes ricinus'e ja Rhipicephalus sanguineus'e vastu.
English: − For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis).
Estonian: − Kirbuinfestatsioonide (Ctenocephalides felis'e ja Ctenocephalides canis'e) tõrjeks.
English: Sarolaner is readily and rapidly absorbed systemically following oral dosing, reaching maximum concentrations in plasma within 3.5 hours (tmax) after administration with a high bioavailability of 86.7%.
Estonian: Sarolaneer imendub suukaudse manustamise järel kiiresti süsteemselt, maksimaalne plasmakontsentratsioon saabub 3,5 tunni (tmax) jooksul pärast manustamist ja biosaadavus on 86,7%.
English: The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors).
Estonian: Sarolaneeri toime peamine sihtmärk putukatel ja lestalistel on ligandisõltuvate klooriioonkanalite (GABA-retseptorite ja glutamaadi retseptorite) funktsionaalne blokaad.
English: − Toxascaris leonina adults;
Estonian: − Toxascaris leonina täiskasvanud vormid;
English: Sarolaner is an acaricide and insecticide belonging to the isoxazoline family.
Estonian: Sarolaneer on akaritsiid ja insektitsiid, mis kuulub isoksasoliini rühma.
English: Pyrantel is a nicotinic acetylcholine (ACh) channel receptor (nAChR) agonist.
Estonian: Püranteel on nikotiin-atsetüülkoliini (ACh) retseptorite (nAChR) agonist.
English: Moxidectin is readily and rapidly absorbed systemically following oral dosing, reaching maximum concentrations in plasma within 2.4 hours (tmax) after administration and with 66.9% bioavailability.
Estonian: Moksidektiin imendub suukaudse manustamise järel kiiresti süsteemselt, maksimaalne plasmakontsentratsioon saabub 2,4 päeva (tmax) pärast manustamist ja biosaadavus on 66,9%.
English: Its principal mode of action is interfering with neuromuscular transmission at the level of the glutamate-gated chloride channels and, to a lesser extent, of GABA (gamma amino butyric acid)-gated channels.
Estonian: Selle peamine toimeviis on glutamaadisõltuvate klooriioonkanalite ja vähemal määral GABA-sõltuvate (gammaaminovõihape) ioonkanalite tasemel neuromuskulaarse ülekande häirimine.
English: Ticks on the animal prior to administration or from new infestations after product administration are killed within 48 hours.
Estonian: Nii enne ravimi manustamist loomal olevad puugid kui ka pärast ravimi manustamist ründavad puugid hävivad 48 tunni jooksul.
English: The veterinary medicinal product has immediate and persistent tick killing activity for 5 weeks against Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus and for 4 weeks against Dermacentor reticulatus;
Estonian: Veterinaarravimil on kohene ja püsiv puuke hävitav toime 5 nädalat Ixodes hexagonus'e, lxodes ricinus'e ning Rhipicephalus sanguineus'e puukide ja 4 nädalat Dermacentor reticulatus'e puukide vastu.
English: For dogs with, or at risk from, mixed external and internal parasitic infestations.
Estonian: Koertele, kellel on välis- ja siseparasiitide segainfektsioon või risk selle tekkeks.
English: Maintenance of the efficacy of macrocyclic lactones is critical for Dirofilaria immitis control.
Estonian: Dirofilaria immitis'e kontrolli all hoidmiseks on tähtis makrotsükliliste laktoonide toime säilitamine.
English: The veterinary medicinal product can be used as part of the seasonal treatment of fleas and ticks (replacing treatment with a mono-active flea and tick product) in dogs with diagnosed concurrent gastrointestinal nematode infections.
Estonian: Kirbu- ja puugi- ning seedetrakti nematoodide infestatsioonide ravi Veterinaarravimit võib kasutada osana hooajalisest kirbu- ja puugivastasest tõrjestrateegiast (asendades sellega monoaktiivse kirpude ja puukide tõrjevahendi) koertel, kellel on diagnoositud ka seedetrakti nematoodide infektsioon.
English: Sarolaner, moxidectin, pyrantel (as embonate)
Estonian: Sarolaneer, moksidektiin, püranteel (embonaadina)
English: The veterinary medicinal product should be administered at a dose of 1.2-2.4 mg/kg of sarolaner, 0.024-0.048 mg/kg of moxidectin and 5-10 mg/kg of pyrantel in accordance with the following table:
Estonian: Veterinaarravimit manustatakse annuses 1,2-2,4 mg sarolaneeri kg kehamassi kohta, 0,024-0,048 mg moksidektiini kg kehamassi kohta ja 5-10 mg püranteeli kg kehamassi kohta järgneva tabeli alusel.
English: Sarolaner exhibits higher functional potency to block insect/acarine receptors compared to mammalian receptors.
Estonian: Sarolaneeril on suurem funktsionaalne tugevus putukate/lestaliste retseptorite blokeerimiseks võrreldes imetajate retseptoritega.
English: The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in dogs intended for breeding.
Estonian: Veterinaarravimi ohutus tiinuse ja laktatsiooni perioodil või aretuses kasutatavatel koertel ei ole piisavalt tõestatud.
English: In a laboratory study, the product was well tolerated in dogs with a deficient multidrug-resistanceprotein 1 (MDR1 -/-) following single oral administration at 3 times the recommended dose.
Estonian: Laboriuuringus talusid puuduva multiravimiresistentse proteiiniga 1 (MDR1 -/-) koerad ravimit hästi suukaudse manustamise järgselt 3-kordse soovitatava annusega.
English: Tablet is debossed with the sarolaner strength on one face of the tablet.
Estonian: Tableti ühele küljele on pressitud tableti (sarolaneeri) tugevust näitav number.
English: Butylhydroxytoluene (E321) Pigment blend 018 (E110, E129, E132) Hydroxypropylcellulose Silica, colloidal anhydrous Magnesium stearate Maize starch
Estonian: Butüülhüdroksütolueen (E 321) Pigmendisegu 018 (E 110, E 129, E 132) Hüdroksüpropüültselluloos Kolloidne veevaba ränidioksiid Magneesiumstearaat Maisitärklis
English: Prevention of heartworm disease and angiostrongylosis:
Estonian: Südameusstõve ja angiostrongüloosi ennetamine
English: If based on veterinarian opinion re-administration(s) of the product is required, any subsequent administration(s) must follow the minimum 1-month interval schedule.
Estonian: Kui loomaarsti hinnangul on vajalik ravimit korduvalt manustada, peab iga järgneva manustamiskorra vahele jääma vähemalt 1 kuu.
English: − Ancylostoma caninum L4 larvae, immature adults (L5) and adults;
Estonian: − Ancylostoma caninum'i L4 vastsed, ebaküpsed täiskasvanud (L5) ja täiskasvanud vormid;
English: Sarolaner blocks GABA- and glutamate-gated chloride channels in the central nervous system of insects and acarines.
Estonian: Sarolaneer blokeerib GABA- ja glutamaadisõltuvaid klooriioonkanaleid putukate ning lestaliste kesknärvisüsteemis.
English: This results in flaccid paralysis and eventual death of parasites exposed to the drug.
Estonian: Tulemuseks on ravimiga kokkupuutunud parasiidi edasine paralüüs ja lõpuks surm.
English: Pyrantel mimics the agonist effects of ACh through high affinity binding to subtype specific ionophoric nAChRs in nematodes, while not binding at muscarinic mAChRs.
Estonian: Püranteel jäljendab ACh agonistlikke toimeid tänu suure afiinsusega seondumisele nematoodide spetsiifiliste ionofoorsete nACh retseptorite alltüübiga, kuid ei seondu muskariinsete mACh retseptoritega.
English: The veterinary medicinal product is exclusively indicated when use against ticks or fleas and gastrointestinal nematodes is indicated at the same time.
Estonian: See veterinaarravim on näidustatud ainult siis, kui on näidustatud samaaegne kasutamine puukide või kirpude ja seedetrakti nematoodide vastu.
English: − For the prevention of angiostrongylosis by reducing the level of infection with immature adult
Estonian: − Angiostrongüloosi ennetamiseks tänu Angiostrongylus vasorum'i ebaküpsete täiskasvanud vormide (L5) infektsiooni vähendamisele.
English: Pyrantel is active against immature stages (L5) and adults of Toxocara canis, adults of Ancylostoma caninum, Toxascaris leonina and Uncinaria stenocephala.
Estonian: Püranteel toimib Toxocara canis'e ebaküpsete (L5) ja täiskasvanud vormide ning Ancylostoma caninum'i, Toxascaris leonina ja Uncinaria stenocephala täiskasvanud vormide vastu.
English: Hydrolysed vegetable protein Gelatin
Estonian: Hüdrolüüsitud taimevalk
English: moxidectin (mg)
Estonian: moksidektiin (mg)
English: No adverse reactions were observed in 8-weeks old healthy puppies administered with up to 5 times the maximum recommended dose for 7 consecutive monthly administrations.
Estonian: Tervetele 8-nädalastele kutsikatele kuni viiekordse maksimaalse annuse manustamisel seitsmel järjestikusel igakuisel manustamiskorral ei ole kõrvaltoimeid täheldatud.
English: For fleas, the onset of efficacy is within 12 to 24 hours of attachment for five weeks after product administration.
Estonian: Toime kirpude vastu saabub pärast ravimi manustamist 12-24 tunni jooksul alates kirbu kinnitumisest ning kestab viis nädalat.
English: EU/2/19/243/001 (3 mg / 0.06 mg / 12.5 mg, 1 tablet) EU/2/19/243/002 (3 mg / 0.06 mg / 12.5 mg, 3 tablets) EU/2/19/243/003 (3 mg / 0.06 mg / 12.5 mg, 6 tablets) EU/2/19/243/004 (6 mg / 0.12 mg / 25 mg, 1 tablet) EU/2/19/243/005 (6 mg / 0.12 mg / 25 mg, 3 tablets) EU/2/19/243/006 (6 mg / 0.12 mg / 25 mg, 6 tablets) EU/2/19/243/007 (12 mg / 0.24 mg / 50 mg, 1 tablet) EU/2/19/243/008 (12 mg / 0.24 mg / 50 mg, 3 tablets) EU/2/19/243/009 (12 mg / 0.24 mg / 50 mg, 6 tablets)
Estonian: EU/2/19/243/001 (3 mg / 0,06 mg / 12,5 mg, 1 tablett) EU/2/19/243/002 (3 mg / 0,06 mg / 12,5 mg, 3 tabletti) EU/2/19/243/003 (3 mg / 0,06 mg / 12,5 mg, 6 tabletti) EU/2/19/243/004 (6 mg / 0,12 mg / 25 mg, 1 tablett) EU/2/19/243/005 (6 mg / 0,12 mg / 25 mg, 3 tabletti) EU/2/19/243/006 (6 mg / 0,12 mg / 25 mg, 6 tabletti) EU/2/19/243/007 (12 mg / 0,24 mg / 50 mg, 1 tablett) EU/2/19/243/008 (12 mg / 0,24 mg / 50 mg, 3 tabletti)
English: Sarolaner binding to these receptors prevents the uptake of chloride ions by GABA and glutamate gated ion channels, thus resulting in increased nerve stimulation and death of the target parasite.
Estonian: Nende retseptoritega seondumise tõttu ei lase sarolaneer GABA- ja glutamaadisõltuvatel ioonkanalitel haarata klooriioone, põhjustades sellega sihtparasiidi tugevnenud närvistimulatsiooni ning surma.
English: EU/2/19/243/010 (24 mg / 0.48 mg / 100 mg, 1 tablet) EU/2/19/243/011 (24 mg / 0.48 mg / 100 mg, 3 tablets) EU/2/19/243/012 (24 mg / 0.48 mg / 100 mg, 6 tablets) EU/2/19/243/013 (48 mg / 0.96 mg / 200 mg, 1 tablet) EU/2/19/243/014 (48 mg / 0.96 mg / 200 mg, 3 tablets) EU/2/19/243/015 (48 mg / 0.96 mg / 200 mg, 6 tablets) EU/2/19/243/016 (72 mg / 1.44 mg / 300 mg, 1 tablet) EU/2/19/243/017 (72 mg / 1.44 mg / 300 mg, 3 tablets) EU/2/19/243/018 (72 mg / 1.44 mg / 300 mg, 6 tablets)
Estonian: EU/2/19/243/009 (12 mg / 0,24 mg / 50 mg, 6 tabletti) EU/2/19/243/010 (24 mg / 0,48 mg / 100 mg, 1 tablett) EU/2/19/243/011 (24 mg / 0,48 mg / 100 mg, 3 tabletti) EU/2/19/243/012 (24 mg / 0,48 mg / 100 mg, 6 tabletti) EU/2/19/243/013 (48 mg / 0,96 mg / 200 mg, 1 tablett) EU/2/19/243/014 (48 mg / 0,96 mg / 200 mg, 3 tabletti) EU/2/19/243/015 (48 mg / 0,96 mg / 200 mg, 6 tabletti) EU/2/19/243/016 (72 mg / 1,44 mg / 300 mg, 1 tablett) EU/2/19/243/017 (72 mg / 1,44 mg / 300 mg, 3 tabletti) EU/2/19/243/018 (72 mg / 1,44 mg / 300 mg, 6 tabletti)
English: Sarolaner is slowly eliminated from plasma (half-life of approximately 12 days) via biliary excretion and elimination through the faeces with minor contributions of metabolic clearance.
Estonian: Sarolaneer eritub plasmast aeglaselt (poolväärtusaeg ligikaudu 12 päeva) sapi ja roojaga, väike osa on ka metaboolsel kliirensil.
English: The product should only be used in dogs when treatment of ticks / fleas and gastrointestinal nematodes is indicated at the same time.
Estonian: Ravimit võib kasutada ainult koertel, kelle puhul on näidustatud samaaegne puukide/kirpude ja seedetrakti nematoodide vastane ravi.
English: − Toxocara canis immature adults (L5) and adults;
Estonian: − Toxocara canis'e ebaküpsed täiskasvanud (L5) ja täiskasvanud vormid;
English: Tablet strength 72 mg/1.44 mg/300 mg
Estonian: Tableti tugevus 72 mg/1,44 mg/300 mg
English: Tablet strength 48 mg/0.96 mg/200 mg
Estonian: Tableti tugevus 48 mg/0,96 mg/200 mg
English: A reddish-brown colored, pentagon shaped tablet with rounded edges.
Estonian: Punakaspruuni värvuse ja ümarate servadega viisnurkse kujuga tabletid.
English: Moxidectin is active against adults of Toxocara canis, L4 larvae and immature stages (L5) of Ancylostoma caninum, L4 of Dirofilaria immitis and immature stages (L5) of Angiostrongylus vasorum.
Estonian: Moksidektiin toimib Toxocara canis'e täiskasvanud vormide, Ancylostoma caninum'i L4 vastsete ja ebaküpsete vormide (L5), Dirofilaria immitis'e L4 vormide ningAngiostrongylus vasorum'i ebaküpsete vormide (L5) vastu.
English: The veterinary medicinal product also provides concurrent efficacy for the prevention of heartworm disease and angiostrongylosis.
Estonian: Veterinaarravimil on samal ajal ka südameusstõve ja angiostrongüloosi ennetav toime.
English: Calcium hydrogen phosphate anhydrous
Estonian: Nisuidud Veevaba kaltsiumvesinikfosfaat
English: This veterinary medicinal product is not effective against adult D. immitis.
Estonian: See veterinaarravim ei toimi D. immitis'e täiskasvanud vormide vastu, kuid juhuslik manustamine täiskasvanud südameussidega nakatunud koertele ei tohiks olla ohtlik.
English: sarolaner 3 mg/moxidectin 0.06 mg/pyrantel (as embonate) 12.5 mg sarolaner 6 mg/moxidectin 0.12 mg/pyrantel (as embonate) 25 mg sarolaner 12 mg/moxidectin 0.24 mg/pyrantel (as embonate) 50 mg sarolaner 24 mg/moxidectin 0.48 mg/pyrantel (as embonate) 100 mg sarolaner 48 mg/moxidectin 0.96 mg/pyrantel (as embonate) 200 mg sarolaner 72 mg/moxidectin 1.44 mg/pyrantel (as embonate) 300 mg
Estonian: sarolaneeri 3 mg / moksidektiini 0,06 mg / püranteeli (embonaadina) 12,5 mg sarolaneeri 6 mg / moksidektiini 0,12 mg / püranteeli (embonaadina) 25 mg sarolaneeri 12 mg / moksidektiini 0,24 mg / püranteeli (embonaadina) 50 mg sarolaneeri 24 mg / moksidektiini 0,48 mg / püranteeli (embonaadina) 100 mg sarolaneeri 48 mg / moksidektiini 0,96 mg / püranteeli (embonaadina) 200 mg sarolaneeri 72 mg / moksidektiini 1,44 mg / püranteeli (embonaadina) 300 mg
English: Moxidectin is slowly eliminated from plasma (half-life of approximately 11 days) via biliary excretion and elimination through the faeces with minor contributions of metabolic clearance.
Estonian: Moksidektiin eritub plasmast aeglaselt (poolväärtusaeg ligikaudu 11 päeva) sapi ja roojaga, väike osa on ka metaboolsel kliirensil.
English: The product was well tolerated in dogs with a deficient multidrug-resistance-protein 1 (MDR1 -/-).
Estonian: Puuduva multiravimiresistentse proteiiniga 1 (MDR1 -/-) koerad taluvad ravimit hästi.
English: Tablet strength 24 mg/0.48 mg/100 mg
Estonian: Tableti tugevus 24 mg/0,48 mg/100 mg
English: Ectoparasites
Estonian: KÕRVALTOIMED
English: Gastrointestinal nematodes
Estonian: Seedetrakti nematoodid
English: A single treatment is efficacious for the treatment of gastrointestinal nematodes.
Estonian: Seedetrakti nematoodide raviks on tõhus ühekordne ravi.
English: This interference leads to the opening of the chloride channels on the postsynaptic junction to allow the inflow of chloride ions.
Estonian: Selle tagajärjel avanevad postsünaptilised kloorikanalid ja suureneb klooriioonide liikumine rakku.
English: Dose
Estonian: Meglumiin
English: Tablet strength 12 mg/0.24 mg/50 mg
Estonian: Tableti tugevus 12 mg/0,24 mg/50 mg
English: − For the treatment of tick infestations.
Estonian: − Puugiinfestatsioonide raviks koertel.
English: Tablet strength 3 mg/0.06 mg/12.5 mg
Estonian: Tableti tugevus 3 mg/0,06 mg/ 12,5 mg
English: Tablet strength 3 mg/0.06 mg/ 12.5 mg
Estonian: Tableti tugevus 3 mg/0,06 mg/12,5 mg
English: Tablet strength 6 mg/0.12 mg/25 mg
Estonian: Tableti tugevus 6 mg/0,12 mg/25 mg
English: Lactose monohydrate Sodium starch glycolate type A Meglumine
Estonian: Laktoosmonohüdraat A-tüüpi naatriumtärklisglükolaat
English: for dogs 1.25-2.5 kg for dogs >2.5-5 kg for dogs >5-10 kg for dogs >10-20 kg for dogs >20-40 kg for dogs >40-60 kg
Estonian: koertele kehamassiga 1,25-2,5 kg koertele kehamassiga >2,5-5 kg koertele kehamassiga >5-10 kg koertele kehamassiga >10-20 kg koertele kehamassiga >20-40 kg koertele kehamassiga >40-60 kg
English: For the treatment of gastrointestinal roundworm and hookworm infections:
Estonian: Seedetrakti ümarusside infektsioonide ravi
English: Simparica Trio chewable tablets for dogs 1.25-2.5 kg Simparica Trio chewable tablets for dogs >2.5-5 kg Simparica Trio chewable tablets for dogs >5-10 kg Simparica Trio chewable tablets for dogs >10-20 kg Simparica Trio chewable tablets for dogs >20-40 kg Simparica Trio chewable tablets for dogs >40-60 kg sarolaner/moxidectin/pyrantel
Estonian: Simparica Trio närimistabletid koertele kehamassiga 1,25-2,5 kg Simparica Trio närimistabletid koertele kehamassiga > 2,5-5 kg Simparica Trio närimistabletid koertele kehamassiga > 5-10 kg Simparica Trio närimistabletid koertele kehamassiga > 10-20 kg Simparica Trio närimistabletid koertele kehamassiga > 20-40 kg Simparica Trio närimistabletid koertele kehamassiga > 40-60 kg sarolaneer/moksidektiin/püranteel
English: Simparica Trio chewable tablets for dogs 1.25-2.5 kg Simparica Trio chewable tablets for dogs >2.5-5 kg Simparica Trio chewable tablets for dogs >5-10 kg Simparica Trio chewable tablets for dogs >10-20 kg Simparica Trio chewable tablets for dogs >20-40 kg Simparica Trio chewable tablets for dogs >40-60 kg
Estonian: Simparica Trio närimistabletid koertele kehamassiga 1,25-2,5 kg Simparica Trio närimistabletid koertele kehamassiga > 2,5-5 kg Simparica Trio närimistabletid koertele kehamassiga > 5-10 kg Simparica Trio närimistabletid koertele kehamassiga > 10-20 kg Simparica Trio närimistabletid koertele kehamassiga > 20-40 kg Simparica Trio närimistabletid koertele kehamassiga > 40-60 kg
English: PACKAGE LEAFLET: Simparica Trio chewable tablets for dogs 1.25-2.5 kg Simparica Trio chewable tablets for dogs >2.5-5 kg Simparica Trio chewable tablets for dogs >5-10 kg Simparica Trio chewable tablets for dogs >10-20 kg Simparica Trio chewable tablets for dogs >20-40 kg Simparica Trio chewable tablets for dogs >40-60 kg
Estonian: PAKENDI INFOLEHT Simparica Trio närimistabletid koertele kehamassiga 1,25-2,5 kg Simparica Trio närimistabletid koertele kehamassiga >2,5-5 kg Simparica Trio närimistabletid koertele kehamassiga >5-10 kg Simparica Trio närimistabletid koertele kehamassiga >10-20 kg Simparica Trio närimistabletid koertele kehamassiga >20-40 kg Simparica Trio närimistabletid koertele kehamassiga >40-60 kg
English: Wheat germ
Estonian: Raviskeem
English: The European Commission issued a decision on 1 July 2010.
Estonian: Euroopa Komisjon võttis oma otsuse vastu 1. juulil 2010.
English: 2 Article 20 of Regulation (EC) No 726/2004.
Estonian: 2 Määruse (EÜ) nr 726/2004 artikkel 20.
English: Ref. EMEA/727399/2009 rev. EMEA/H/A-31/1097
Estonian: London, 1. juuli 2010 Viide: EMEA/727399/2009 rev. EMEA/H/A-31/1097
English: What are the recommendations for patients and prescribers?
Estonian: Millised on soovitused patsientidele ja ravimite määrajatele?
English: Most of these medicines are authorised nationally.
Estonian: Enamik neid ravimeid on heaks kiidetud riikliku menetluse kaudu.
English: Article 31 of Directive 2001/83/EC as amended, referral under Community interest.
Estonian: Muudetud direktiivi 2001/83/EÜ artikkel 31, esildise tegemine ühenduse huvides.
English: A communication containing the key messages of this review will be distributed to doctors at national level.
Estonian: Käesoleva läbivaatamise peamisi seisukohti sisaldavat teatist levitatakse arstide hulgas liikmesriikides.
English: • These medicines should only be used in accordance with the updated prescribing information.
Estonian: • Neid ravimeid tuleks kasutada üksnes kooskõlas määramist puudutava ajakohastatud teabega.
English: The medicines are only used by MR specialists.
Estonian: Kõnealuseid ravimeid kasutavad ainult MRI-spetsialistid.
English: It may affect several organs such as the liver, lungs and heart.
Estonian: Haigus võib mõjutada mitut organit, näiteks maksa, kopse ja südant.
English: This included information from preclinical and clinical studies, as well as information provided by the companies that make the medicines.
Estonian: Need andmed sisaldasid prekliinilistest ja kliinilistest uuringutest, samuti kõnealuseid ravimeid tootvatelt ettevõtetelt saadud teavet.
English: • information on the cases of NSF reported for each agent.
Estonian: • teavet iga aine puhul täheldatud NSFi juhtude kohta.
English: Two of these products - OptiMARK (gadoversetamide) and Vasovist (gadofosveset) - have received a marketing authorisation that is valid throughout the European Union (EU).
Estonian: Kaks nendest - OptiMARK (gadoversetamiid) ja Vasovist (gadofosveset) - on saanud kogu Euroopa Liidus kehtiva müügiloa.
English: The review was carried out under ‘Article 31'1 and ‘Article 20'2 referrals.
Estonian: Läbivaatamine toimus artikli 311 ja artikli 202 kohaste esildismenetluste korras.
English: The Committee also concluded that an additional factor that may contribute to the risk of NSF is the way these medicines are used (such as the dose, how often they are given and for how long).
Estonian: Samuti jõudis komitee järeldusele, et üks NSFi riski mõjutada võiv lisategur on nende ravimite kasutamisviis (näiteks annus, manustamise sagedus ja kestus).